| Increased antifungal drug resistance in clinical isolates of Cryptococcus neoformans in Uganda KD Smith, B Achan, KH Hullsiek, TR McDonald, LH Okagaki, AA Alhadab, ... Antimicrobial agents and chemotherapy 59 (12), 7197-7204, 2015 | 194 | 2015 |
| Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study J Rhein, BM Morawski, KH Hullsiek, HW Nabeta, R Kiggundu, L Tugume, ... The Lancet infectious diseases 16 (7), 809-818, 2016 | 183 | 2016 |
| Amikacin pharmacokinetic-pharmacodynamic analysis in pediatric cancer patients AA Alhadab, MA Ahmed, RC Brundage Antimicrobial agents and chemotherapy 62 (4), 10.1128/aac. 01781-17, 2018 | 21 | 2018 |
| Population pharmacokinetics of sertraline in healthy subjects: a model-based meta-analysis AA Alhadab, RC Brundage The AAPS Journal 22 (4), 73, 2020 | 14 | 2020 |
| Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose. AR Minchom, MG Krebs, BC Cho, SH Lee, NB Leighl, B O'Neil, JK Sabari, ... Journal of Clinical Oncology 41 (16_suppl), 9126-9126, 2023 | 6 | 2023 |
| Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis AA Alhadab, J Rhein, L Tugume, A Musubire, DA Williams, M Abassi, ... Journal of pharmacokinetics and pharmacodynamics 46, 565-576, 2019 | 6 | 2019 |
| Physiologically‐Based Pharmacokinetic Model of Sertraline in Human to Predict Clinical Relevance of Concentrations at Target Tissues AA Alhadab, RC Brundage Clinical Pharmacology & Therapeutics 108 (1), 136-144, 2020 | 5 | 2020 |
| Semimechanistic modeling to guide venetoclax coadministration with ritonavir and digoxin AA Alhadab, AH Salem, KJ Freise Clinical and Translational Science 13 (3), 555-562, 2020 | 5 | 2020 |
| Analysis of US Food and Drug Administration oncology approvals on the characterization of hepatic impairment effect and dosing recommendations DZ Yang, A Alhadab, K Parivar, DD Wang, M Elmeliegy Clinical Pharmacology & Therapeutics 112 (4), 782-790, 2022 | 4 | 2022 |
| Adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis J Rhein, HK Hupler, BM Morawski Conference on Retroviruses and Opportunistic Infections, 22-26, 2015 | 3 | 2015 |
| Case–control matching‐guided exposure‐efficacy relationship for avelumab in patients with urothelial carcinoma P Soltantabar, A Alhadab, J Hibma, S Roychoudhury, DD Wang, C Bello, ... CPT: Pharmacometrics & Systems Pharmacology 12 (12), 2001-2012, 2023 | 1 | 2023 |
| A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer G Galffy, I Lugowska, EV Poddubskaya, BC Cho, MJ Ahn, JY Han, WC Su, ... ESMO open 8 (3), 101173, 2023 | 1 | 2023 |
| Population pharmacokinetics of sertraline: a model-based meta-analysis A Alhadab, R Brundage JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 43, S91-S91, 2016 | 1 | 2016 |
| 6MO Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study N Leighl, AR Minchom, KHH Lee, MG Krebs, BC Cho, YJ Kim, ... ESMO Open 9, 2024 | | 2024 |
| STAGGERING VENETOCLAX AND DIGOXIN ADMINISTRATION TO MINIMIZE GASTROINTESTINAL P-GLYCOPROTEIN INHIBITION: A MODEL-BASED ANALYSIS AA Alhadab, A Salem, KI Freise Clinical Pharmacology & Therapeutics| 103, S21, 2018 | | 2018 |
| A SEMI-MECHANISTIC MODEL OF RITONAVIR CYP3A INHIBITION AND PHARMACOKINETIC INTERACTION WITH CYP3A SUBSTRATE VENETOCLAX AA Alhadab, A Salem, KI Freise Clinical Pharmacology & Therapeutics| 103, S22, 2018 | | 2018 |
| The Utility of Pharmacometrics in Drug Development and Pharmacotherapy of Antimicrobials AA Alhadab University of Minnesota, 2018 | | 2018 |
| The pharmacodynamics of Sertraline as Anti-fungal A Alhadab, J Rhein, KH Hullsiek, D Meya, D Boulware, R Brundage JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 43, S91-S91, 2016 | | 2016 |
| PREDICTED ANTI-CRYPTOCOCCAL EFFICACY OF SERTRALINE IN HIV-INFECTED UGANDANS AA Alhadab, RC Brundage, T ASTRO-CM Clinical Pharmacology & Therapeutics 99, S28, 2016 | | 2016 |
| Biologically Active Secondary Metabolites from Red Sea Cyanobacteria AA Alhadab | | 2010 |
